Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clover Health InvestmentsCLOV +2.04%82 3-Year EBITDA Growth Rate is 32.30% as of Jun. 2026, which is 43% above its 10-year median of 22.60. GuruFocus rates CLOV with a GF Score™ of 82/100 and a GF Value™ of $4.44 (Fairly Valued). The stock has 2 warning signs investors should review. Among 16 Healthcare Plans companies, Clover Health Investments ranks better than 81.25% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 32.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Clover Health Investments was 59.40% per year. The lowest was -30.30% per year. And the median was 22.60% per year.
Clover Health Investments (NAS:CLOV) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Clover Health Investments 3-Year EBITDA Growth Rate Related Terms
CLOV vs PGNY, ALHC, PFHO: 3-Year EBITDA Growth Rate Comparison
For the Healthcare Plans subindustry, Clover Health Investments's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clover Health Investments 3-Year EBITDA Growth Rate vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Clover Health Investments's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Clover Health Investments's 3-Year EBITDA Growth Rate falls into.
Clover Health Investments 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 32.30% mean?
Clover Health Investments (CLOV) has a 3-Year EBITDA Growth Rate of 32.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Clover Health Investments and its competitors. This is 43% above median its historical median of 22.60. According to the industry distribution chart, Clover Health Investments ranks #3 out of 16 companies in the Healthcare Plans industry, placing it in the top 18.7%.
Is Clover Health Investments' 3-Year EBITDA Growth Rate too high?
Clover Health Investments' current 3-Year EBITDA Growth Rate of 32.30% is 43% above median its 10-year median of 22.60. Based on the distribution chart, Clover Health Investments ranks #3 out of 16 companies in the Healthcare Plans industry, which is in the top quartile — a strong position relative to peers. Overall, Clover Health Investments has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Clover Health Investments' 3-Year EBITDA Growth Rate compare to PGNY and ALHC?
According to the Healthcare Plans industry distribution chart, Clover Health Investments ranks #3 out of 16 companies for 3-Year EBITDA Growth Rate. This places Clover Health Investments in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Plans company?
A good 3-Year EBITDA Growth Rate depends on the Healthcare Plans industry context. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Clover Health Investments and its competitors. Clover Health Investments's current 3-Year EBITDA Growth Rate is 32.30%, which is 43% above median its own 10-year median of 22.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clover Health Investments stock overvalued right now?
Based on GuruFocus' analysis, Clover Health Investments (CLOV) is currently considered Fairly Valued. The stock's GF Value™ is $4.44, compared to a current price of $4.75 — trading 7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 32.30%, which is 43% above median its 10-year median of 22.60. Clover Health Investments' overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Clover Health Investments (CLOV), the current 3-Year EBITDA Growth Rate is 32.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clover Health Investments (CLOV) Overvalued in 2026?
Based on GuruFocus' analysis, Clover Health Investments stock appears to be overvalued.
The current stock price of $4.75 is trading 7% above its estimated GF Value™ of $4.44.
GuruFocus considers Clover Health Investments to be Fairly Valued.
Key valuation signals for CLOV:
3-Year EBITDA Growth Rate: 32.30% (43% above median its 10-year median of 22.60)
GF Value™: $4.44 vs. price of $4.75 (7% above fair value)
No single metric tells the full story. See the CLOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
82GF Score
Get the complete analysis for CLOV
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLOV has been successfully added to your 
